380 related articles for article (PubMed ID: 8648668)
21. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.
Yu XF; Dawson L; Tian CJ; Flexner C; Dettenhofer M
J Virol; 1998 Apr; 72(4):3412-7. PubMed ID: 9525672
[TBL] [Abstract][Full Text] [Related]
22. Morphological study on biologically distinct vpx/vpr mutants of HIV-2.
Piroozmand A; Khamsri B; Fujita M; Adachi A; Uchiyama T
J Med Invest; 2006 Aug; 53(3-4):271-6. PubMed ID: 16953064
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
Park J; Morrow CD
Virology; 1993 Jun; 194(2):843-50. PubMed ID: 8503189
[TBL] [Abstract][Full Text] [Related]
24. Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly.
Craven RC; Bennett RP; Wills JW
J Virol; 1991 Nov; 65(11):6205-17. PubMed ID: 1717718
[TBL] [Abstract][Full Text] [Related]
25. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R
Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862
[TBL] [Abstract][Full Text] [Related]
26. Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins.
Dettenhofer M; Yu XF
J Virol; 1999 Jun; 73(6):4696-704. PubMed ID: 10233929
[TBL] [Abstract][Full Text] [Related]
27. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease.
Ross EK; Fuerst TR; Orenstein JM; O'Neill T; Martin MA; Venkatesan S
AIDS Res Hum Retroviruses; 1991 May; 7(5):475-83. PubMed ID: 1873082
[TBL] [Abstract][Full Text] [Related]
28. Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.
Shehu-Xhilaga M; Crowe SM; Mak J
J Virol; 2001 Feb; 75(4):1834-41. PubMed ID: 11160682
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag.
Yu FH; Huang KJ; Wang CT
Viruses; 2020 Jan; 12(1):. PubMed ID: 31906562
[TBL] [Abstract][Full Text] [Related]
30. Properties of avian retrovirus particles defective in viral protease.
Stewart L; Schatz G; Vogt VM
J Virol; 1990 Oct; 64(10):5076-92. PubMed ID: 1697912
[TBL] [Abstract][Full Text] [Related]
31. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
Paxton W; Connor RI; Landau NR
J Virol; 1993 Dec; 67(12):7229-37. PubMed ID: 8230445
[TBL] [Abstract][Full Text] [Related]
32. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles.
Park J; Morrow CD
J Virol; 1992 Nov; 66(11):6304-13. PubMed ID: 1383561
[TBL] [Abstract][Full Text] [Related]
33. Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells.
Sunseri N; O'Brien M; Bhardwaj N; Landau NR
J Virol; 2011 Jul; 85(13):6263-74. PubMed ID: 21507971
[TBL] [Abstract][Full Text] [Related]
34. The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein.
Shehu-Xhilaga M; Hill M; Marshall JA; Kappes J; Crowe SM; Mak J
J Virol; 2002 May; 76(9):4331-40. PubMed ID: 11932399
[TBL] [Abstract][Full Text] [Related]
35. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
Liao WH; Wang CT
Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885
[TBL] [Abstract][Full Text] [Related]
36. Effects of human immunodeficiency virus type 1 transframe protein p6* mutations on viral protease-mediated Gag processing.
Chiu HC; Wang FD; Chen YA; Wang CT
J Gen Virol; 2006 Jul; 87(Pt 7):2041-2046. PubMed ID: 16760407
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus type 2 Vpx-Gag interaction.
Pancio HA; Ratner L
J Virol; 1998 Jun; 72(6):5271-5. PubMed ID: 9573303
[TBL] [Abstract][Full Text] [Related]
38. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.
Kotler M; Simm M; Zhao YS; Sova P; Chao W; Ohnona SF; Roller R; Krachmarov C; Potash MJ; Volsky DJ
J Virol; 1997 Aug; 71(8):5774-81. PubMed ID: 9223465
[TBL] [Abstract][Full Text] [Related]
39. A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions.
Kulkosky J; BouHamdan M; Geist A; Pomerantz RJ
Virology; 1999 Mar; 255(1):77-85. PubMed ID: 10049823
[TBL] [Abstract][Full Text] [Related]
40. Human immunodeficiency virus type 2 vpx protein augments viral infectivity.
Kappes JC; Conway JA; Lee SW; Shaw GM; Hahn BH
Virology; 1991 Sep; 184(1):197-209. PubMed ID: 1714662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
